Home / Biopharma / EPS Estimates Lure Passive Investments: Novavax, Inc. (NASDAQ:NVAX), HealthSouth Corporation (NYSE:HLS)

EPS Estimates Lure Passive Investments: Novavax, Inc. (NASDAQ:NVAX), HealthSouth Corporation (NYSE:HLS)

Novavax, Inc. (NASDAQ:NVAX) [Trend Analysis] moved down reacts as active mover, shares a decrease -0.78% to traded at $1.27 and the percentage gap between open changing to regular change was -0.78%.

Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have ranked NVAX in recent few months. In ratings table the NVAX given BUY ratings by 2 analysts in current phase. The 0 number of analyst/s have SELL recommendation for current month on NVAX. While 6 number of analysts gave ratings for HOLD in current. As per remarks given by WSJ, overall consensus pool recommend it as Hold security.

The stock was assessed in terms of profitability as current quarter EPS estimate trends showed $-0.23 at current month while compared with $-0.25 in a month ago. The stock next year first quarter current estimate trend for EPS was for $-0.17 and on annual basis FY 2016 estimate trends at current was for $-1.05 as compared to one month ago of $-1.09, and for next year per share earnings estimates have $-0.68.

The firm’s current ratio calculated as 4.70 for the most recent quarter. The firm past twelve months price to sales ratio was 21.80 and price to cash ratio remained 1.15. As far as the returns are concern, the return on equity was recorded as -189.10% and return on investment was -53.60% while its return on asset stayed at -61.50%. The firm has total debt to equity ratio measured as 6.35.

HealthSouth Corporation (NYSE:HLS) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 3.07% to $42.01.

The HLS held a rough session during the week but was ready to get some critical analysis. The stock was assessed by a pool of analysts at WSJ and came out with some serious outcomes not to be avoided before making investment. The HLS ratings chart showed that 2 gave HOLD ratings for the current month as 2 analysts opting for Overweight option for same period, whereas, 1 analyst out of pool gave UNDERWEIGHT rating. For stocks’ current month, 5 analysts opted for BUY ratings as compared to 1 opting for SELL in the same period. The stock price target chart showed average price target of 45.00 as compared to current price of 42.01.

Taking look on per share earnings estimates, its next year first quarter current estimate trend for EPS was for $0.65 and on annual basis FY 2016 estimate trends at current was for $2.55 as compared to one month ago of $2.55, and for next year per share earnings estimates have $2.74.

The share price of HLS attracts active investors, as stock price of week volatility recorded 1.90%. The stock is going forward to its 52-week low with 41.37% and lagging behind from its 52-week high price with -2.59%.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Stocks Luring Investors with Juicy Profitability Figures: Arrowhead Pharmaceuticals (NASDAQ:ARWR), Skyline Medical (NASDAQ:SKLN)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) kept active in profitability ratio analysis, on current situation shares price …

Leave a Reply

Your email address will not be published. Required fields are marked *